A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® - Full Text View

A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler® (Symb NIS)

This study has been completed.

First Received on September 20, 2007. Last Updated on June 8, 2009 History of Changes

Sponsor:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00532922

Purpose

The purpose of this study is to investigate real practices of treatment with Symbicort Turbuhaler for 3 months in asthma and patient compliance.

Condition	Phase
Asthma	Phase IV

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	A 3-Month Non-Interventional Study of Asthmatics Treatment With Symbicort® Turbuhaler®

Resource links provided by NLM:

MedlinePlus related topics: Asthma

Drug Information available for: Symbicort

U.S. FDA Resources

Further study details as provided by AstraZeneca:

Enrollment:	310
Study Start Date:	April 2007
Study Completion Date:	November 2007

Groups/Cohorts
1 Chinese asthma patient prescribed Symbicort® Turbuhaler®

Eligibility

Ages Eligible for Study:	6 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Natural History, longitudinal, defined population

Criteria

Inclusion Criteria:

Provision of informed consent
Asthmatics who has been prescribed Symbicort according to physician's judgement
Usage of Symbicort should follow local prescribing information

Exclusion Criteria:

Not being involved in the planning and conduct of the study (applies to both AstraZeneca staff or staff at the study site)
No previous enrolment in the present study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00532922

Locations

China, Anhui
Research Site
Hefel, Anhui, China
China, Fujian
Research Site
Fuzhou, Fujian, China
China, Guangdong
Research Site
Guangzhou, Guangdong, China
Research Site
Shenzhen, Guangdong, China
China, Henan
Research Site
Zhengzhou, Henan, China
China, Hubei
Research Site
Wuhan, Hubei, China
China, Hubel
Research Site
Wuhan, Hubel, China
China, Jiangsu
Research Site
Nanjong, Jiangsu, China
Research Site
Suzhou, Jiangsu, China
China, Liaoning
Research Site
Shenyand, Liaoning, China
China, Shandong
Research Site
Qingdao, Shandong, China
China, Shanxi
Research Site
Taiyuan, Shanxi, China
Research Site
Xi'an, Shanxi, China
China, Sichuan
Research Site
Chengdu, Sichuan, China
China, Zhejiang
Research Site
Wenzhou, Zhejiang, China
China
Research Site
Beijing, China
Research Site
Chongqing, China
Research Site
Hangzhou, China
Research Site
Shanghai, China

Sponsors and Collaborators

AstraZeneca

Investigators

Principal Investigator:	Zhou Xin	Shanghai First People's Hospital
Principal Investigator:	Hong Jianguo	Shanghai First People's Hospital

More Information

No publications provided

ClinicalTrials.gov Identifier:	NCT00532922 History of Changes
Other Study ID Numbers:	NIS-RCN-SYM-2006/1
Study First Received:	September 20, 2007
Last Updated:	June 8, 2009
Health Authority:	Not required for this study:

Additional relevant MeSH terms:

Asthma
Bronchial Diseases
Respiratory Tract Diseases
Lung Diseases, Obstructive
Lung Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Symbicort
Budesonide
Anti-Asthmatic Agents

Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Anti-Inflammatory Agents

ClinicalTrials.gov processed this record on February 09, 2012